BTIG on Monopar Therapeutics (MNPR): '2026 is expected to be a big year'
Tweet Send to a Friend
BTIG analyst Jeet Mukherjee reiterated a Buy rating and $104.00 price target on Monopar Therapeutics (NASDAQ: MNPR).The analyst comments "2026 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
